Jonathan Behr, PhD, brings over 10 years of venture and venture creation experience to the Dementia Discovery Fund (DDF) including as managing director of a mission driven fund.
Dr. Behr currently serves as Partner for the DDF. Prior to joining the DDF, Dr. Behr was the first managing director of the JDRF T1D Fund, a growing $90 million mission-driven fund focused on venture investments in companies developing solutions for type 1 diabetes. In less than three years, he led the development of the fund’s investment strategy with the board of directors, built an investment team, and led 14 of the fund’s first investments including Semma Tx (acquired by VRTX), Pandion Therapeutics (PAND), and Provention Bio (PRVB). He has held senior venture creation roles, including Principal at PureTech Ventures (PRTC) and Vice President of New Ventures for Enlight Biosciences. In his prior roles he was a director or observer on more than 14 venture backed company boards.
Dr. Behr earned a PhD in Biological Engineering from Massachusetts Institute of Technology as a Howard Hughes Medical Institute fellow, and received his BS in Bioengineering summa cum laude as phi-beta-kappa co-valedictorian from Rice University.